Effect of [D-Trp6]LHRH infusion on prolactin secretion by perifused rat pituitary cells.

Torres-Aleman I, Fernández M, Debeljuk L, Charro AL

Regulatory peptides1 Jul 1987Cited by 3 (Europe PMC)

PMID2957725DOI10.1016/0167-0115(87)90046-2PepBankPUB-02957725

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In perifused pituitary cells from triptorelin-pretreated rats, prolactin secretion was lower than in vehicle-injected controls throughout infusion.
In plain wordsIn lab tests, pituitary cells from triptorelin-pretreated rats released less prolactin than cells from vehicle-treated rats.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseProlactin secretion after pretreatment
Study
ratn: not reported in source
Perifused pituitary cells
Comparator
Vehicle-injected controls
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
50 micrograms · subcutaneous · 1 h before sacrificeAs given in this study (rat).
Source sentences
Summary
In animals pretreated in vivo with 50 micrograms of [D-Trp6]LHRH (s.c.) 1 h before sacrifice, PRL secretion by the rat pituitary cell perifusion system was significantly lower than vehicle-injected controls throughout the entire [D-Trp6]LHRH infusion period.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of a superactive agonistic analog of luteinizing hormone-releasing hormone (LHRH), [D-Trp6]LHRH on prolactin (PRL) secretion by perifused rat pituitary cells was investigated.
Report a problemFND-0295772503
02LabIn vitro (cells)Efficacy outcome
In perifused rat pituitary cells, triptorelin infusion significantly reduced prolactin secretion, starting around 30 minutes and lasting up to 1.5-2 hours.
In plain wordsIn lab tests with rat pituitary cells, triptorelin reduced prolactin release.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBasal prolactin secretion
Study
ratn: not reported in source
Perifused pituitary cells
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.5 ng/min · 2-3 hAs given in this study (rat).
Source sentences
Summary
Constant infusion of [D-Trp6]LHRH (0.5 ng/min) for 2-3 h elicited a significant decrease in PRL secretion by these cells.
2 context sentences(design, population, supporting numbers)
Summary · context
This decrease in PRL release started ca. 30 min after the beginning of the infusion with the LHRH analog and lasted up to 1.5-2 h.
Summary · context
The effect of a superactive agonistic analog of luteinizing hormone-releasing hormone (LHRH), [D-Trp6]LHRH on prolactin (PRL) secretion by perifused rat pituitary cells was investigated.
Report a problemFND-0295772501
03LabIn vitro (cells)Efficacy outcome
In rat pituitary cells, triptorelin increased LH secretion during the first 30 minutes, followed by a return toward control values.
In plain wordsIn lab tests with rat pituitary cells, triptorelin first increased LH release, which then approached control levels.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
MixedLH secretion
Study
ratn: not reported in source
Perifused pituitary cells
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
[D-Trp6]LHRH significantly stimulated luteinizing hormone (LH) secretion during the first 30 min of peptide infusion; thereafter, LH levels began to return to control values.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of a superactive agonistic analog of luteinizing hormone-releasing hormone (LHRH), [D-Trp6]LHRH on prolactin (PRL) secretion by perifused rat pituitary cells was investigated.
Report a problemFND-0295772502
04LabIn vitro (cells)Efficacy outcome
In rat pituitary cells, triptorelin infusion slightly but significantly impaired TRH-stimulated prolactin secretion.
In plain wordsIn lab tests with rat pituitary cells, triptorelin slightly reduced prolactin release stimulated by TRH.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTRH-stimulated prolactin secretion
Study
ratn: not reported in source
Perifused pituitary cells
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
On the other hand, thyrotropin-releasing hormone (TRH)-stimulated PRL secretion was slightly, but significantly imparied by [D-Trp6]LHRH infusion
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of a superactive agonistic analog of luteinizing hormone-releasing hormone (LHRH), [D-Trp6]LHRH on prolactin (PRL) secretion by perifused rat pituitary cells was investigated.
Report a problemFND-0295772504
05LabIn vitro (cells)Mechanism
In rat pituitary cells, triptorelin did not affect dopamine inhibition of prolactin release.
In plain wordsIn lab tests with rat pituitary cells, triptorelin did not change dopamine's inhibition of prolactin release.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeDopamine inhibition of prolactin release
Study
ratn: not reported in source
Perifused pituitary cells
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
On the other hand, thyrotropin-releasing hormone (TRH)-stimulated PRL secretion was slightly, but significantly imparied by [D-Trp6]LHRH infusion, while dopamine (DA) inhibition of PRL release was unaffected by this same treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of a superactive agonistic analog of luteinizing hormone-releasing hormone (LHRH), [D-Trp6]LHRH on prolactin (PRL) secretion by perifused rat pituitary cells was investigated.
Report a problemFND-0295772505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.